Showing results (31-40 of 37) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 37 results.
The Lancet. Rheumatology|November 15, 2021
Humoral and cellular immunogenicity to a second dose of COVID-19 vaccine BNT162b2 in people receiving methotrexate or targeted immunosuppression: a longitudinal cohort studySatveer K Mahil, Katie Bechman, Antony Raharja, et al.
European Journal of Immunology|May 17, 2013
CD161 expression characterizes a subpopulation of human regulatory T cells that produces IL-17 in a STAT3-dependent mannerBehdad Afzali, Peter J Mitchell, Francis C Edozie, et al.
Brain Communications|August 19, 2021
Amyotrophic lateral sclerosis transcriptomics reveals immunological effects of low-dose interleukin-2Ilaria Giovannelli, Nadhim Bayatti, Abigail Brown, et al.
BMJ Open|December 8, 2021
Study protocol: Minimum effective low dose: anti-human thymocyte globulin (MELD-ATG): phase II, dose ranging, efficacy study of antithymocyte globulin (ATG) within 6 weeks of diagnosis of type 1 diabetesCharlotte S Wilhelm-Benartzi, Sarah E Miller, Sylvaine Bruggraber, et al.
Lancet (London, England)|September 21, 2025
Minimum effective low dose of antithymocyte globulin in people aged 5-25 years with recent-onset stage 3 type 1 diabetes (MELD-ATG): a phase 2, multicentre, double-blind, randomised, placebo-controlled, adaptive dose-ranging trialChantal Mathieu, Julie Wych, A Emile J Hendriks, et al.
The Lancet. Oncology|April 30, 2021
Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational studyLeticia Monin, Adam G Laing, Miguel Muñoz-Ruiz, et al.
Lancet (London, England)|May 12, 2025
Efficacy and safety of low-dose IL-2 as an add-on therapy to riluzole (MIROCALS): a phase 2b, double-blind, randomised, placebo-controlled trialGilbert Bensimon, P Nigel Leigh, Timothy Tree, et al.
Pageof 4